Boehringer Licenses ProBioGen’s GlymaxX Technology

Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement under which Boehringer’s Contract Manufacturing Business will apply ProBioGen’s GlymaxX technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies. According to the company, the technology can be integrated into Boehringer’s high expression CHO-based BI-HEX system. Both companies will jointly market the technology and offer it to customers royalty free. 


“We are very pleased that Boehringer Ingelheim has decided to integrate our GlymaxX technology into their technology portfolio for customer and in-house projects. This is an additional milestone in our long-standing business relationship,” said Volker Sandig, chief scientific officer of ProBioGen AG.

“With the combination of the BI-HEX platform and ProBioGen’s GlymaxX technology we can offer our customers tailored solutions for high titer expression of highly potent antibodies,” said Simon Sturge, corporate senior vice president biopharmaceuticals of Boehringer Ingelheim.